OVERVIEW

This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include breast imaging, oncofertility, breast pathology, surgical oncology, reconstructive microsurgery, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.
Over the past year, advances in clinical trials have demonstrated the utility of antibody-drug conjugates, immunotherapy, genomic assays in hormone receptor-positive breast cancer, and downstaging surgical management of the axilla. The evolution of reconstructive microsurgery in oncoplastic and lymphedema surgery proceeds at a rapid pace. These developments, along with data on resistance to endocrine therapy and therapy targeting the HER2 axis, make individualized management decisions increasingly important in treating patients with breast cancer. Newer radiation therapy treatment strategies and clinical trials in radiation oncology continue to evolve.  Evolving technology in breast imaging, specifically tomosynthesis, is challenging conventional imaging techniques. Breast cancer in young women has become a specialized field in oncology, which is seeing increasing visibility. Inflammatory cancer continues to be a challenging area where new therapeutic concepts are emerging. These breakthroughs allow personalized breast cancer treatments to maximize benefits and minimize treatment toxicities.
The understanding of the HER2 receptor continues to evolve. Key talks in medical oncology will focus on HER2+ breast cancer therapeutics in the metastatic setting, the use of newer agents in metastatic ER+ cancers, and the evolution of immunotherapy as a central theme in the treatment of triple-negative breast cancer. 

TARGET AUDIENCE

This conference is designed for practicing primary care physicians, medical oncologists, radiation oncologists, surgical oncologists, radiologists, residents and fellows in oncology training programs, as well as allied health providers including oncology nurses, mid-level providers (APN and PA), radiation therapists (RTT), and any other clinicians interested or involved in the management and treatment of breast cancer. 

LEARNING OBJECTIVES

1. Assess decision-making process in surgical management of the axilla, including the use of axillary ultrasound to re-stage the axilla after neoadjuvant chemotherapy.
2. Classify evolving concepts in treatment of HER2-low breast cancer.
3. Explain the biology of the HER2 axis and its role in treating metastatic cancer.
4. Define the role of CDK inhibitors in treating metastatic and resistant ER+ cancers.
5. Incorporate the evolving role of clinical trials in radiation therapy.
6. Summarize use of genomic assays for patients who are candidates for ovarian function suppression, including the OFSET CHEMO trial.
7. Assess the impact of advances in breast imaging using PET scanning aimed at the estrogen receptor (FES-PET).
8. Explain the importance of fertility preservation during breast cancer treatment.
9. Appreciate the evolution of antibody drug conjugates as a treatment strategy for advanced breast cancer. 

ACCREDITATION

The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Keck School of Medicine of the University of Southern California designates this activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.